March 2, 2023

Apotex Corp. issues voluntary nationwide recall of brimonidine tartrate ophthalmic solution, 0.15% due to cracks that have developed in some of the units caps of the bottles

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **PrimeTherapeutics.com/DrugRecalls** to review the latest FDA drug recalls.

Apotex Corp. has posted a lot recall of brimonidine tartrate ophthalmic solution.

About this recall:

Apotex Corp. is initiating a voluntary recall at the consumer level for six lots of brimonidine tartrate ophthalmic solution, 0.15% . This recall is being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility and, if so, adverse events may occur.

Brimonidine tartrate ophthalmic solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

What this means to you:

Apotex Corp. is notifying all impacted direct accounts (wholesalers, distributors, warehousing chains, mail order pharmacy and long-term care pharmacy) of this voluntary recall via email and mail (FedEx Standard Overnight) and is arranging for return of all recalled product.

Patients who have received the identified lots or have questions regarding this recall should contact their pharmacy. They should immediately contact their health care provider for medical advice and return the identified lots to Inmar Rx Solutions by contacting at the phone number provided in this press release.

Wholesalers, distributors, warehousing chains, mail order pharmacy and long-term care pharmacy should return the recalled product to the place of purchase. Anyone with an existing inventory of the recalled product should quarantine the recalled lots immediately. Customers who purchased the impacted product directly from Apotex Corp. can call Inmar Rx Solutions at **855.275.1273**, Monday–Friday, 9 a.m.–5 p.m. Eastern Standard Time (EST), to arrange for their return.

Consumers with the impacted units of brimonidine tartrate ophthalmic solution, 0.15%, can contact Inmar Rx Solutions at **855.275.1273**, to receive a recall/return packet including the Recall Stock Response Form (or you may obtain this form from **CLSNetLink.com**).

Consumers with questions regarding this recall can contact Apotex Corp. by phone at **800.706.5575**, Monday–Friday, 8:30 a.m.–5 p.m. Eastern Standard Time (EST) or email at **USCustomerService@Apotex.com**. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.